Related Experiment Video
Updated: May 10, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
Erdheim-Chester disease in a child
1Department of Paediatrics, Xiangya Second Hospital of Central South University, Changsha City, China. zz040217@yahoo.com.cn
Insights
Erdheim-Chester disease (ECD), a rare histiocytosis, typically affects adults. This study highlights interferon-alpha (IFN-alpha) as a safe and effective treatment for a rare pediatric case of ECD.
Area of Science:
- Pediatric Hematology
- Rare Diseases
- Histiocytosis
Background:
- Erdheim-Chester disease (ECD) is a rare systemic non-Langerhans histiocytosis affecting multiple organ systems, predominantly in adults.
- Paediatric ECD is exceptionally rare, posing diagnostic and therapeutic challenges.
Observation:
- A case report of an 11-year-old girl presenting with systemic bone pain and limping.
- Diagnosis was confirmed via clinical presentation, imaging, and iliac bone biopsy.
Findings:
- The patient received subcutaneous interferon-alpha (IFN-alpha) at 3 x 10(6) units thrice weekly for 19 months.
- IFN-alpha treatment demonstrated safety and efficacy in managing the pediatric patient's clinical manifestations.
Implications:
- Interferon-alpha (IFN-alpha) may represent a valuable first-line therapeutic option for pediatric Erdheim-Chester disease.
- Further research into IFN-alpha's role in treating pediatric ECD is warranted.
Abstract:
Erdheim-Chester disease (ECD) is a rare systemic non-Langerhans histiocytosis that affects multiple organ systems. It occurs more often in adults, and paediatric ECD is extremely rare. The diagnosis of ECD can be established based on clinical presentations and imaging but the final diagnosis should be based on biopsy. Treatment of ECD has involved the use of corticosteroids, radiotherapy, chemotherapy, surgery and haematopoietic stem cell transplantation, yet the efficacy of these treatments is difficult to determine. At present, it is thought that the treatment of interferon-alpha (IFN-alpha) is safe and effective for ECD. Herein, we report on an 11-year old girl who was admitted to hospital because of systemic bone pain and limping, and the final diagnosis of ECD was based on evidence provided by her clinical presentation, imaging and biopsy of a lesion of the right ilium. The patient was treated with subcutaneous IFN-alpha at a dosage of 3 x 10(6) units three times weekly for 19 months. We thought that the treatment of IFN-alpha was safe and effective for the girl's clinical manifestations, and IFN-alpha might be a valuable first-line therapy for paediatric ECD.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Hypersensitivity Reactions: Immune-Complex Reactions
Diphtheria
Other Disorders of Digestive System
